ArticleMolecular biology reports2026
Role of MexAB-OprM and MexXY-OprM efflux pumps in carbapenem-resistant Pseudomonas aeruginosa from burn wounds.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPseudomonas aeruginosa remains a major cause of burn wound infections and exhibits a remarkable ability to develop resistance to carbapenems, primarily through multidrug efflux systems belonging to the Resistance-Nodulation-Division (RND) family. This study investigated the contribution of the MexAB-OprM and MexXY-OprM efflux pumps to carbapenem resistance in P. aeruginosa isolates from burn wounds and evaluated the effect of an efflux pump inhibitor on antibiotic susceptibility.
methodsA total of 100 P. aeruginosa isolates were collected from burn patients. Antimicrobial susceptibility to imipenem and meropenem was determined by minimum inhibitory concentration (MIC) assays according to CLSI guidelines. The presence of mexAB-oprM and mexXY-oprM genes was confirmed via PCR. The functional role of efflux activity was assessed using carbonyl cyanide 3-chlorophenylhydrazone (CCCP), a proton-motive force inhibitor, and MIC reductions ≥ 4-fold were interpreted as efflux-mediated resistance.
resultsResistance to imipenem and meropenem was observed in 44% and 27% of isolates, respectively. Among imipenem-resistant isolates, mexXY-oprM was detected in 50% and mexAB-oprM in 18%, while 23% co-presented both systems. In contrast, mexAB-oprM predominated in meropenem-resistant strains (48%), followed by mexXY-oprM (22%). Upon CCCP addition, MICs decreased by ≥ 4-fold in 84% of imipenem-resistant and 52% of meropenem-resistant isolates, suggesting the involvement of efflux pumps (P < 0.05).
conclusionA high prevalence of carbapenem resistance and efflux pump-associated genes was observed among P. aeruginosa isolates from burn wound infections. Significant reductions in carbapenem MICs following CCCP exposure suggest that efflux-mediated mechanisms may contribute to the resistance phenotype in a substantial proportion of isolates. These findings indicate a potential role for efflux activity in carbapenem resistance and warrant further investigation of its clinical and mechanistic significance.
Indexed as
Identifiers
42429867What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.